6-97.4%) suggesting that lymph node tissue should be avoided when possible for testing (39). Either primary or metastatic tissue can be tested for KRAS per the NCCN guidelines (19). KRAS mutational analysis in mCRC represents a negative predictive test by selecting out those patients who are unlikely to respond to anti-EGFR therapy. This represents an important step forward since in the absence of benefit, patients will avoid the potential toxicities and cost of this therapy. The absence of a mutation in KRAS will not guarantee a response and the search for positive biomarkers remains an
area of intense research in mCRC. Results of recent clinical trials (with a focus on KRAS wild type tumors) The first two trials conducted in the pre-KRAS mutational Inhibitors,research,lifescience,medical testing era showed similar efficacy for cetuximab (40) and panitumumab (41) compared to best supportive care with a distinct pattern of the progression-free survival
(PFS) curves in both studies suggesting that a biomarker might explain the later separation Inhibitors,research,lifescience,medical observed. This was later identified as the presence of KRAS mutations in about 40% of patient tumor samples. After the discovery of the find more importance on KRAS mutational status in 2006, investigators analyzed their clinical trials selecting for KRAS status retrospectively and updated Inhibitors,research,lifescience,medical their results to confirm the importance of selecting for the absence of a mutation (Table 1). Table 1 Clinical trials with EGFR inhibitors, KRAS wild-type patients only Cetuximab The first trial conducted with single agent cetuximab compared to best supportive care showed a significant improvement in ORR (13% vs. 0%), PFS (3.7 vs. 1.9 mo, P<0.001) and OS (9.5 vs. 4.8 mo; Inhibitors,research,lifescience,medical P<0.001) when looking at patients with KRAS wild-type tumors only. This trial did not allow
for cross-over upon progression (24). The first combination chemotherapy trial with an EGFR inhibitor was the BOND trial, published in 2004, in the pre-KRAS era. Patients who had previously progressed on irinotecan-based chemotherapy had an overall response rate (ORR) of 22%, a PFS of 4.1 months and OS of 8.6 months when treated with irinotecan and cetuximab while patients Inhibitors,research,lifescience,medical on single-agent cetuximab had an ORR of 10.8%, PFS Rolziracetam 1.5 mo and OS 6.9 mo (42). This trial did not look at KRAS mutational status. These results suggested that EGFR inhibitors could potentially “resensitize” tumors to irinotecan after prior progression to the same agent. The largest trial to date conducted with cetuximab is the CRYSTAL trial that explored cetuximab in combination with FOLFIRI as 1st line therapy (13). An updated analysis published in 2011 revealed that cetuximab given with FOLFIRI improved response rates (57.3% vs. 39.7%, P<0.001), median PFS (9.9 vs. 8.4 mo, P=0.0012) and median OS (23.5 vs. 20.0 mo, P=0.0093) compared to FOLFIRI alone in patients with KRAS wild-type tumors (25). The FDA approved cetuximab in conjunction with FOLFIRI as first-line therapy in July 2012 largely based on the results of this trial.